Benitec Biopharma’s (BNTC) Buy Rating Reaffirmed at Guggenheim

Guggenheim restated their buy rating on shares of Benitec Biopharma (NASDAQ:BNTC) in a research report report published on Tuesday,Benzinga reports. They currently have a $17.00 price target on the biotechnology company’s stock.

Several other analysts also recently issued reports on the stock. JMP Securities upped their price target on shares of Benitec Biopharma from $16.00 to $18.00 and gave the company a “market outperform” rating in a report on Monday, October 14th. Oppenheimer began coverage on Benitec Biopharma in a report on Wednesday, October 16th. They set an “outperform” rating and a $35.00 target price on the stock. Finally, Piper Sandler reissued an “overweight” rating on shares of Benitec Biopharma in a report on Friday, October 18th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $22.60.

Benitec Biopharma Stock Up 2.5 %

Shares of BNTC stock opened at $10.00 on Tuesday. Benitec Biopharma has a fifty-two week low of $2.69 and a fifty-two week high of $12.89. The business has a fifty day simple moving average of $10.22 and a 200-day simple moving average of $9.15. The stock has a market cap of $232.20 million, a P/E ratio of -3.09 and a beta of 0.88.

Institutional Trading of Benitec Biopharma

A number of hedge funds have recently bought and sold shares of BNTC. Janus Henderson Group PLC lifted its stake in shares of Benitec Biopharma by 35.5% during the 1st quarter. Janus Henderson Group PLC now owns 244,491 shares of the biotechnology company’s stock worth $1,266,000 after purchasing an additional 64,092 shares during the period. GAMMA Investing LLC lifted its position in Benitec Biopharma by 53.0% during the second quarter. GAMMA Investing LLC now owns 5,438 shares of the biotechnology company’s stock worth $38,000 after buying an additional 1,884 shares during the period. Simplify Asset Management Inc. acquired a new stake in Benitec Biopharma in the 2nd quarter worth about $358,000. Nantahala Capital Management LLC purchased a new stake in Benitec Biopharma in the 2nd quarter valued at about $5,881,000. Finally, Acuta Capital Partners LLC acquired a new position in shares of Benitec Biopharma during the 3rd quarter valued at about $274,000. Institutional investors and hedge funds own 52.19% of the company’s stock.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.